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Effects of an excitatory amino acid, glutamate, and of ionotropic and metabotropic glutamate receptor agonists on the levels of free intracellular 
calcium, and their specific receptor binding in human SH-SYSY neuroblastoma cells were studied. The calcium response was always biphasic, except 
for AMPA, suggesting both stimulatory and inhibitory effects on free intracellular calcium upon glutamate receptor stimulation, both with 
ionotropic and metabotropic glutamate receptor agonists. Specific binding of glutamate and other glutamate receptor agonists, together with the 
biphasic calcium response, suggests that human SH-SYSY neuroblastoma cells express both ionotropic and metabotropic glutamate receptors. 
These findings shed new light on the use of human SH-SYSY neuroblastoma cells as a human neuronal tumor cell model. 
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1. INTRODUCTION 
The excitatory amino acid, glutamate, causes the 
entry of calcium into neuronal cells through ionotropic 
receptor-gated calcium channels [l], and a release of 
calcium from intracellular nonmitochondrial calcium 
stores through actions on a metabotropic receptor. Glu- 
tamate metabotropic receptor stimulates phospholipase 
C [2], and increases the formation of two second mes- 
sengers, inositol-1,4,5-trisphosphate and diacylglycerol 
[3,4]. Inositol-1,4,5-trisphosphate elevates free intracel- 
lular calcium which regulates a number of cellular signal 
transduction processes, including the activation of pro- 
tein kinase C and calcium/calmodulin-dependent pro- 
tein kinase. Calcium plays a critical role in the toxic cell 
killing and programmed cell death [5,6]. 
The endogenous excitatory amino acid, glutamate, 
activates at least three distinct ionotropic receptors in 
neuronal cells: the N-methyl-u-aspartate (NMDA), the 
ol-amino-3-hydroxy-5-methyl-4-isoxazole propionic 
acid (AMPA) and the kainate receptor subtypes [l]. In 
addition, it also activates a metabotropic receptor that 
is coupled to G protein(s) and linked to inositol phos- 
pholipid metabolism [2,7-91. A selective agonist for the 
metabotropic glutamate receptor is (lS,3R)-l-aminocy- 
clopentane-1,3-dicarboxylic a id (lS,3R-ACPD). 
The effects of glutamate, and of ionotropic and 
*Corresponding author. Fax: (358) (71) 201 265. 
Abbreviations: NMDA, N-methyl-o-aspartate; AMPA, a-amino-3- 
hydroxy-5-methyl+isoxazole propionic acid; lS,3R-ACPD, (lS,3R)- 
1-aminocyclopentane-1,3-dicarboxylic acid; [Ca*‘],, free intracellular 
calcium. 
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metabotropic glutamate receptor agonists, on the levels 
of free intracellular calcium, and their specific receptor 
binding, were used to assess the expression of glutamate 
receptors in human SH-SYSY neuroblastoma cells. 
2. MATERIALS AND METHODS 
2.1. Reagents 
L-[G-3H]Glutamic acid (54 Wmmol) and Aqueous Counting Scin- 
tillant were obtained from Amersham (Arlington Hts., IL, USA). 
Fura-2/AM was obtained from Molecular Probes Inc. (Eugene, OR, 
USA). lS,3R-ACPD was from To& Neuramin (Bristol, UK). Dul- 
becco’s modified Eagle medium (DMEM), foetal calf serum (FCS), 
penicillin-streptomycin solution and Hanks’ balanced salt solution 
(HBSS; Ca”- and Mg*‘-free) were obtained from Gibco (Paisley, 
UK). All the other chemicals were obtained from Sigma Co. (St. 
Louis, MO, USA). 
2.2. Cell culture 
The human neuroblastoma SH-SYSY cell line [lo] was obtained 
through Dr. S. Pahlman (Department of Pathology, University of 
Uppsala, Sweden). The cells were cultured in Dulbecco’s modified 
Eagle medium supplemented with 7% inactivated foetal calf serum and 
50 U/ml penicillin and 50 &ml streptomycin, and incubated at 37“ C 
in 5% CO* in an air ventilated humidified incubator. The cells used 
in the experiments were cultured to confluency and harvested by 
0.02% EDTA in phosphate-buffered saline. The cells were grown in 
75 cm* cell culture flasks purchased from Costar (Cambridge, MA, 
USA). 
2.3. Measurement of free intracellular calcium ([Cd’],) 
The levels of [Ca”], were measured using the acetoxymethyl ester 
of the fluorescent calcium probe, fura- (fura-Z/AM). Aliquots (1 ml) 
of the cells were loaded with 3 PM fura-2/AM with a constant agita- 
tion for 45 min at 37°C. After loading the cells were washed twice with 
ice-cold HBSS and resuspended in HBSS (without Ca*’ and Mg*‘, 
including 1 mg/ml bovine serum albumin and 10 mM o-glucose) to 
give a final cell concentration of 3 x lo6 cell/ml. One ml of the cell 
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suspension and 1 ml prewarmed HBSS were placed in a quartz cuvette, 
in which the final cell concentration was 1.5 x lo6 cells/ml. Free intra- 
cellular calcium was measured using a Hitachi F-4000 spectrofluoro- 
meter equipped with a thermostated cuvette holder and a magnetic 
stirrer applying the method described by Tsien et al., 1985 [I 11. Free 
intracellular calcium was calculated using the equation. 
where Kd = 224 nM, F = the relative level of intracellular fluorescence, 
F,,,,, = the relative level of fura- fluorescence in 7.5 mM EGTA after 
cell lysis with 10% sodium dodecyl sulphate, and F,, = the relative 
level of fluorescence with 7 mM calcium added after the determination 
of F,,,. Before the measurements, CaCI, was added directly into the 
cuvette to give the final concentration of calcium of 1.2 mM in the 
medium. Twenty PM of MnCl, was used to quench the extracellular 
fura-2lAM. 
2.4. Receptor binding assay 
Specific displacement of r$H]glutamate by glutamate or specific 
ionotropic or metabotropic glutamate receptor agonists was measured 
using intact SH-SYSY neuroblastoma cells. All incubations were done 
in Tris buffer (50 mM Tris, pH 7.4 adjusted with acetic acid) to avoid 
Na’ and Cl- ions which may interfere with the binding of the agonists 
with the glutamate receptors [12]. The cells were simultaneously incu- 
bated with 10 nM L-[‘HIglutamate, and with 10 nM - 1 mM of unla- 
belled agonist for 15 min at 4°C. Incubation volume was 250 ~1 
(lo&200 pg protein/tube). After that, the cells were centrifuged, and 
the cell pellets were washed three times with ice-cold Tris-buffer. The 
washed pellets were agitated for 24 h in liquid scintillant, and thereaf- 
ter the samples were subjected to liquid scintillation counting (LKB 
Wallac, Turku, Finland). 
2.5. Statistics 
The results were analyzed for statistical significance with one-way 
analysis of variance and with Duncan’s multiple-range test. P < 0.05 
was considered statistically significant. 
3. RESULTS AND DISCUSSION 
Functional or morphological expression of glutamate 
receptors in human SH-SYSY neuroblastoma cells has 
not been reported earlier. We report here that both 
glutamate and selective ionotropic and metabotropic 
glutamate receptor agonists induce a slow biphasic re- 
sponse in free intracellular calcium ([Ca*‘]J in human 
SH-SYSY neuroblastoma cells. A rapid initial increase 
is followed by a sustained decrease in cell calcium, sug- 
gesting both stimulatory and inhibitory effects on 
[Ca*‘]i upon ionotropic and metabotropic glutamate re- 
ceptor stimulation. Specific binding of glutamate and 
other glutamate receptor agonists, together with gluta- 
mate receptor agonist-induced biphasic calcium re- 
sponse, suggests that human SH-SYSY neuroblastoma 
ceils express both ionotropic and metabotropic gluta- 
mate receptors. 
High concentrations (500 ,uM-3 mM) of glutamate 
and of specific ionotropic glutamate receptor agonists 
induced a rapid initial increase in [Ca*+]i which was 
followed by a sustained decrease. Low concentrations 
(C 500 PM) of glutamate receptor agonists caused only 
a sustained decrease in [Ca’+], (for individual tracings, 
see Fig. 1). The increase in [Ca*+], (Fig. 2) was dose- 
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Fig. 1. Representative tracings of glutamate-induced slow oscillations 
of free intracellular calcium in SH-SY5Y neuroblastoma cells. Trac- 
ings of an increase (3 mM; upper tracing) and a decrease (300 ,uM; 
lower tracing) in free intracellular calcium for glutamate are shown. 
The tracings for other agonists closely resembled those of glutamate. 
dependent after glutamate, NMDA, and kainate at a 
concentration range from 500 ,uM to 3 mM. On the 
contrary, AMPA did not cause a significant increase in 
[Ca”],. This is not, however, surprising because AMPA 
is known to affect mainly sodium fluxes through an 
action on its receptor [l]. The metabotropic glutamate 
receptor agonist lS,3R-ACPD was effective only at a 
3 mM concentration (Fig. 2). The time to reach the 
maximum of [Ca*‘]i decreased ose-dependently by glu- 
tamate and kainate. After glutamate, the time of the 
maximum in [Ca*‘], decreased from 29 (500 PM) to 19 
s (3 mM), whereas after kainate it decreased from 6 (1 
mM) to 3 s (3 mM). On the contrary, AMPA prolonged 
the time for the maximum in [Ca*‘]i from 19 (300 PM) 
to 64 s (3 mM). NMDA did not have a consistent effect 
on the calcium peaking time which varied between 12 
and 17 s. 
The differences between the effects of glutamate, 
NMDA, kainate and AMPA on [Ca”], are probably 
partially due to conformational changes that take place 
in receptor-gated calcium channels. The increase of 
[Ca*‘]i by 1 S,3R-ACPD occurred only at a high concen- 
tration (3 mM) at 17 s. It is, however, in agreement with 
the time for the onset of an increase in [Ca”], induced 
by other agonists coupled to calcium-mobilizing recep- 
tors [ 13-151. These data suggest hat ionotropic rather 
than metabotropic glutamate receptors predominate the 
temporal pattern [16] of calcium increases upon stimu- 
lation of human SH-SYSY neuroblastoma cells by glu- 
tamate or specific ionotropic glutamate receptor ag- 
onists. In addition to the opening of receptor-gated cal- 
cium channels [17], and intracellular release of calcium 
[4], secondary depolarization of neuronal membrane, 
and subsequent opening of voltage-dependent [ 18,191 
calcium channels may contribute to the elevation of 
[Ca*‘],. Here we report an integrated calcium response 
to glutamate receptor agonists, which does not exclude, 
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Fig. 2. Maxima of increases in free intracellular calcium induced by excitatory amino acids in SH-SYSY neuroblastoma cells. For calcium peaking 
times by different glutaminergic agonists at different concentrations, ee the text. Data are expressed as mean + S.E.M. of 3-4 experiments done 
in duplicate. Dimethylsulfoxide (DMSO) (1%) vehicle was always used as a control. *P < 0.05; one-way analysis of variance and Duncan’s 
multiple-range test. 
however, rapid calcium oscillations [4] with a wide 
range of local alterations in [Ca*‘],. In fact, excitable 
cells are continuously susceptible to depolarizing firing 
via other neuronal cells, and this direct depolarization 
may also contribute to the elevated [Ca”], through volt- 
age-dependent calcium channels [ 18,191. If calcium is 
not removed from the cytoplasm, it may reach toxic or 
desensitizing levels [ 18,201. 
There are several effective mechanisms in SH-SYSY 
neuroblastoma cells to stabilize [Ca*‘]i, i.e. calcium 
pumps remove calcium from the cytosol to the extracel- 
lular space, or to intracellular calcium stores, such as 
endoplasmic reticulum, mitochondria and nucleus 
[18,20,21]. Moreover, calcium binding by cytosolic pro- 
teins, including calmodulin, parvalbumin, and vitamin 
D-dependent calcium binding protein, are effective 
buffering processes [20], essential for the protection of 
excited neuronal cells against calcium-induced cell kill- 
ing [18]. 
An initial increase in [Ca2’]i by glutamate, NMDA, 
kainate, AMPA, and lS,3R-ACPD was followed by a 
sustained ecrease in [Ca*‘]i which reached a maximum 
at 3 min; there was always a dose-dependent decrease 
in [Ca2+li which was, however, reversed at high doses 
(Fig. 3). At low agonist concentrations, however, only 
224 
a decrease in [Ca*+]i occurred (see Figs. 1 and 3). The 
levels of [Ca*‘]i remained decreased at least for a follow- 
up period of 10 min (data not shown). The basal [Ca”], 
in unstimulated SH-SYSY neuroblastoma cells was 
131 f 4 nM (mean f S.E.M.). The maximal decrease 
was 30-55 nM depending on the agonist. The normal 
physiological range of [Ca*+]i in unstimulated cells is 
between 50 and 200 nM [22]; maintaining of [Ca*+]i in 
the physiological concentration range is essential for 
neuronal cells [23]. Inspite that the integrated decrease 
in [Ca2+]i always remained at a physiological range, 
rapid oscillations in [Ca2’], are possible. 
The sustained decrease of [Ca*‘]i below the resting 
level was an unexpected finding. Excessive glutamate 
receptor stimulation may be followed by receptor desen- 
sitization [24] which thereby may also change the bal- 
ance between [Ca2+]i elevations, calcium buffering, and 
calcium removing systems. Moreover, glutamate recep- 
tor-induced elevation of [Ca*‘]i may be associated with 
neuronal hyperpolarization [16] which would result in 
a relative desensitization of voltage-dependent calcium 
channels toward depolarizing firing. The biphasic 
[Ca’+], response upon glutamate receptor stimulation 
provides evidence that two separate processes are in- 
volved in these calcium changes. 
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Fig. 3. Maxima of decreases in free intracellular calcium induced by excitatory amino acids in SH-SYSY neuroblastoma cells. Calcium decrease 
was measured at 3 min post-stimulation of the cells by the agonists. Data are expressed as mean + S.E.M. of 334 experiments done in duplicate. 
DMSO (1%) vehicle was always used as a control. Statistical analysis of the data is as given in the legend to Fig. 2. 
The receptor binding data suggest that both ion- 
otropic and metabotropic glutamate receptor agonists 
exhibit specific binding to their receptors in human SH- 
SYSY neuroblastoma cells (Table I). Together with the 
glutamate receptor agonist-induced biphasic slow cal- 
cium responses this receptor binding data provide evi- 
dence for the expression of glutamate receptors in 
Table I 
Specific displacement of L-[3H]glutamate by ionotropic and 
metabotropic glutamate receptor agonists 
Agonist Specific displacement (fmol/mg protein) 
L-Glutamate 38.0 ? 9 
NMDA 23.2 rt: 6 
Kainate 15.8 f 3 
AMPA 23.7 f 9 
1 S,3R-ACPD 23.5 f 9 
Values are expressed as mean + S.E.M. of three experiments done in 
duplicate. The concentration of the L_I’H]glutamate was 10 nM and 
that of the unlabelled agonists 1 mM. Displacement was biphasic in 
nature. It was the greatest both at low (10 nM) and high (1 mM) 
agonist concentrations, whereas only little specific displacement was 
found at intermediate concentrations (data not shown). Non-specific 
binding ranged between 9 and 26% of total binding. 
human SH-SYSY neuroblastoma cells. Involvement of 
both receptor-gated calcium channels, and the stimula- 
tion of G protein coupled calcium-mobilizing second 
messenger systems, in glutamate-induced changes of 
[Ca”], are likely. It increases the functional diversity 
and plasticity of human SH-SYSY neuroblastoma cells 
upon glutamate receptor stimulation. The use of human 
SH-SYSY neuroblastoma cells may be useful in explor- 
ing excitatory amino acid-induced processes in human 
neuronal tumor cells. 
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